Abstract

Hand–foot skin reaction (HFSR), among the most significant adverse effects of sorafenib, has been limiting the clinical benefits of this frontline drug in treating various malignant tumors. The mechanism underlying such toxicity remains poorly understood, hence the absence of effective intervention strategies. In the present study, we show that vascular endothelial cells are the primary cellular target of sorafenib-induced HFSR wherein soluble heparin-binding epidermal growth factor (s-HBEGF) mediates the crosstalk between vascular endothelial cells and keratinocytes. Mechanistically, s-HBEGF released from vascular endothelial cells activates the epidermal growth factor receptor (EGFR) on keratinocytes and promotes the phosphorylation of c-Jun N-terminal kinase 2 (JNK2), which stabilizes sirtuin 1 (SIRT1), an essential keratinization inducer, and ultimately gives rise to HFSR. The administration of s-HBEGF in vivo could sufficiently induce hyper-keratinization without sorafenib treatment. Furthermore, we report that HBEGF neutralization antibody, Sirt1 knockdown, and a classic SIRT1 inhibitor nicotinamide could all significantly reduce the sorafenib-induced HFSR in the mouse model. It is noteworthy that nicotinic acid, a prodrug of nicotinamide, could substantially reverse the sorafenib-induced HFSR in ten patients in a preliminary clinical study. Collectively, our findings reveal the mechanism of vascular endothelial cell-promoted keratinization in keratinocytes and provide a potentially promising therapeutic strategy for the treatment of sorafenib-induced HFSR.

Highlights

  • Sorafenib is a multikinase inhibitor that targets the receptor tyrosine and serine/threonine kinases involved in tumor progression and tumor angiogenesis.[1,2,3,4] It has been approved in many countries as frontline therapy for patients with advanced hepatocellular carcinoma, advanced renal cell carcinoma, and metastatic thyroid carcinoma

  • We examined the states of proliferation and differentiation in keratinocytes, with keratin 5 (KRT5) and keratin 14 (KRT14) applied as proliferation markers, and keratin 1 (KRT1), keratin 10 (KRT10), loricrin (LORICRIN) and involucrin (IVL) characterizing differentiation.[16,25,26]

  • Our findings unprecedentedly identify the role of the vascular endothelial cell as the primary cellular target in sorafenib-induced hand–foot skin reaction (HFSR)

Read more

Summary

Introduction

Sorafenib is a multikinase inhibitor that targets the receptor tyrosine and serine/threonine kinases involved in tumor progression and tumor angiogenesis.[1,2,3,4] It has been approved in many countries as frontline therapy for patients with advanced hepatocellular carcinoma, advanced renal cell carcinoma, and metastatic thyroid carcinoma. For most of these patients, sorafenib is the only treatment producing favorable therapeutic effects. Clinical trial reports from ClinicalTrial.gov and other published papers have demonstrated that the incidence percentage of sorafenib-induced HFSR ranged from 30% to as high as 76%.5–9 For patients with severe HFSR, dose reduction or interruption is needed, which undesirably reduces the therapeutic efficiency of sorafenib or even unlooses the progression of cancer.[10,11]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call